Congress schedules xylazine to fight street-drug contamination crisis
H.R. 1266 — Combating Illicit Xylazine Act · Filed by Jimmy Panetta (D-CA) · 113 cosponsors · Introduced Feb 12, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds xylazine (a veterinary sedative increasingly misused as a street drug) to Schedule III of the Controlled Substances Act, making it a regulated controlled substance. It allows veterinarians and pharmacies to continue dispensing xylazine for legitimate animal use without new registration burdens, gives manufacturers a one-year grace period before full Schedule III security and labeling rules apply, and requires the DEA and FDA to track xylazine distribution and report to Congress on illicit use patterns.
Why we flagged it
The bill's core function is to regulate an emerging drug-abuse threat by placing xylazine under federal control, with reporting and tracking mechanisms. It is a straightforward public-health intervention, not a tax or appropriations measure.
What the text implies
- The one-year labeling grace period may delay visibility into xylazine supply chains, potentially allowing illicit diversion to continue unmonitored during the transition window.
- Exempting existing manufacturers from capital security expenditures creates a compliance gap: older facilities may operate under weaker security standards than new Schedule III entrants, potentially creating diversion risk.
The full analysis lists 4 implications of this text.
Who stands to gain
existing xylazine manufacturers (exempted from immediate capital security upgrades); veterinary pharmaceutical suppliers (retain market access with minimal disruption)